Next-generation lipid nanocarriers for Parkinson's therapy: nose-to-brain innovations and clinical prospects

Parkinson's disease (PD) remains one of the most formidable challenges in central nervous system (CNS) drug delivery due to the restrictive blood–brain barrier (BBB) and limited efficacy of current dopaminergic therapies. Created in BioRender. Fahmy, S. (2025) https://BioRender.com/vsusgrv.